DeLong Mark Jeffrey — SEC Form 4 filings
SEC reporting owner CIK 1856078. 18 Form 4 filings on record with FilingPulse; latest filed 2026-05-14.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-01-17 to 2026-05-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 14 legs across 14 filings — 25,703 shares, $1,120,888 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 9,913 shares @ $56.90 ($564,050) in Apellis Pharmaceuticals, Inc., filed 2024-03-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Chief Business & Strat Officer | 18 | — | 14 legs · 25,703 sh · $1,120,888 | 28 |
Form 4 filings — DeLong Mark Jeffrey
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Code (U): 114,591 · Grant/award (A): 41,250 · Disposition to issuer (D): 41,250 · Grant/award (A): 19,006 · Disposition to issuer (D): 19,006 · Grant/award (A): 36,606 · +15 more | EDGAR |
| 2026-02-13 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 368 @ $22.15 | EDGAR |
| 2026-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 36,606 @ $0 | EDGAR |
| 2026-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 3,371 @ $21.77 | EDGAR |
| 2026-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,334 @ $19.79 | EDGAR |
| 2026-01-15 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,780 @ $22.19 | EDGAR |
| 2025-06-11 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 82,500 (derivative) @ $19.39 | EDGAR |
| 2025-02-12 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 363 @ $28.54 | EDGAR |
| 2025-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 365 @ $29.52 | EDGAR |
| 2025-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,396 @ $30.43 | EDGAR |
| 2025-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,235 @ $29.96 · Grant/award (A): 28,508 @ $0 | EDGAR |
| 2025-01-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,599 @ $28.70 | EDGAR |
| 2024-08-13 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Option exercise (M): 5,201 @ $13.85 · Option exercise (M): 5,201 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 9,913 @ $56.90 | EDGAR |
| 2024-02-13 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 597 @ $67.77 | EDGAR |
| 2024-01-31 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 367 @ $64.14 | EDGAR |
| 2024-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,384 @ $65.00 | EDGAR |
| 2024-01-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 16,963 @ $0 · Sale (S): 1,631 @ $66.81 · Grant/award (A): 24,666 (derivative) @ $66.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1856078 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →